Valeant Pharmaceuticals International has extended the expiration of its $51 billion offer to take over Allergan from Aug. 15 to the end of this year, without any new changes in the new improved conditions laid out on June 2. It made the announcement after receiving pledges from Allergan shareholders that ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.